Plasma companies are closing US collection centers and drawing more plasma from each donor, just as record numbers of cash-strapped Americans line up to sell

OBSERVATION: The US plasma-collection industry — supplier of ~70% of the world's plasma — is flipping from a decade-long center buildout premised on donor scarcity to a productivity-led contraction, at the same moment its donor base is swelling with economically distressed Americans. Three 2026 legs.

(1) FEWER CENTERS, MORE PLASMA. Grifols announced on April 24, 2026 the closure of 29 US donation centers while stating it 'expects to grow its overall plasma collection volumes in the US' — explicitly a margin play ('We have a clear opportunity to drive efficiencies with our US plasma collections and thereby contribute to our margin improvement objective' — Jordi Balsells, President Plasma Procurement). Its H1 2026 SEC filing (July 28) shows ~280 US centers, down from 'more than 300' at the April announcement. CSL Plasma (300+ US centers) signed a supply agreement with Haemonetics in August 2026 to transition US centers to NexSys PCS devices with Persona PLUS: base Persona technology is 'clinically shown to yield +9% to 12% more plasma per donation on average' (Haemonetics' own claim, directly fetched), and Persona PLUS (FDA-cleared February 2026) adds mid-single-digit further gains 'at a lower cost-per-liter.' The binding constraint is moving from finding donors to extracting more per donation.

(2) DONOR SUPPLY SURGING ON ECONOMIC DISTRESS. NBC News (Feb 12, 2026): ~200,000 people donate daily; $4.7B paid to donors in 2025; 62.5M liters collected last year, +30% since 2022; 1,200+ US centers (more than Costco locations); typical pay $45–65 per donation, and companies already adjust pay seasonally to donor supply (cutting in December when holiday-cash donors surge, raising in January). Middle-class donors — laid-off finance workers, paralegals, households earning $120k — now sell plasma for car payments and preschool tuition. Academic work (via Public Health Watch): plasma centers concentrate in low-income areas; a center opening makes nearby young adults ~18% less likely to open a new payday loan and correlates with ~12% lower crime — plasma pay functions as an income floor, so donor supply rises exactly when the economy squeezes households, which is also exactly when processors need fewer donors per liter.

(3) POLICY RESHUFFLE AT THE BORDER. US plasma is largely exported for fractionation abroad and re-imported as finished medicine ($6.2B plasma exports in 2024). The 100% Section 232 pharmaceutical tariff reaches all remaining companies September 29, 2026; BIS's September 21 notice names plasma-derived therapies eligible for a 0% rate — but only from listed jurisdictions or via case-by-case 'urgent U.S. health need' determinations (requests opened Sept 23; none yet decided). Separately, Grifols is substituting Egyptian plasma for US plasma in ex-US markets after EMA approval (~1M liters collected in 2026, targeting up to 3M liters/year by 2029; Egypt already supplies ~25% of the plasma Grifols uses outside the US) — the first material routing-around of the US donor base by a major fractionator.

Inference (kept separate from evidence)

if per-donor yield technology spreads across CSL and Grifols (~600 US centers combined) while distressed-donor supply keeps growing, the industry's donor-compensation cost per liter falls — and donor pay is the adjustable variable, as the documented seasonal pay adjustments show processors already treat it. The households for whom plasma pay is an income floor face an industry that structurally needs less of them per liter collected.

Contradictory evidence (marked non-supporting)

peer-reviewed supply-sustainability analysis (Vox Sanguinis, 2025) shows global immunoglobulin demand grew ~12%/year 2010–2018, the IVIg market is projected from $13.4B (2023) to ~$25B (2032), Europe meets only ~63% of its plasma-medicine demand domestically, and 2017–2022 shortages forced doctors to cut treatment doses. On this reading the closures are efficiency inside secular growth, not surplus: collections must keep growing long-term, donor recruitment remains the strategic constraint, and one demand shock (a new immunoglobulin indication, or a geopolitical supply split) re-flips the constraint overnight.

Biggest unknown

there is no post-Persona-PLUS data on donor compensation per donation or per liter — does donor pay actually fall as yield technology and the distressed-donor surge land together, or does immunoglobulin demand growth absorb both? And the September 29 tariff carve-out is undecided: whether plasma-derived therapies get broad 0% treatment or firm-by-firm urgent-need rulings determines whether the collect-in-US / fractionate-abroad / re-import loop keeps working at all.